Search Result

Results for "

LRRK2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	LRRK2 (62) AMPK (2) Apoptosis (2) Aurora Kinase (1) Autophagy (1) Bcr-Abl (1) BCRP (1) Drug Intermediate (1) DYRK (1) E3 Ligase Ligand-Linker Conjugates (2) ERK (4) Ferroptosis (1) Fluorescent Dye (1) GSK-3 (2) Hippo (MST) (1) IKK (3) Integrin (1) Interleukin Related (3) JAK (3) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (1) Microtubule/Tubulin (1) Mitophagy (1) MMP (1) MNK (1) Mps1 (1) NF-κB (3) P-glycoprotein (3) PKD (3) PROTAC Linkers (2) PROTACs (7) Reference Standards (4) RET (1) Ser/Thr Protease (2) Small Interfering RNA (siRNA) (3) Src (1) Syk (1) TNF Receptor (3) TNK1 (2) VEGFR (1) YAP (1) α-synuclein (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (2) Inflammation/Immunology (11) Neurological Disease (62)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: LRRK2

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100411

MLi-2 10+ Cited Publications	LRRK2	Neurological Disease
MLi-2, a chemical probe, is an orally active and highly selective *LRRK2* inhibitor with an IC₅₀ of 0.76 nM. MLi-2 has the potential for Parkinson’s disease .

HY-15796

GNE0877 2 Publications Verification	LRRK2	Neurological Disease
GNE0877 is a highly selective, orally active and brain-penetrant *LRRK2* inhibitor with an IC₅₀ of 3 nM and a K_i of 0.7 nM. GNE0877 can be used for the research of neuroscience .

HY-13687

IKK 16 Maximum Cited Publications 29 Publications Verification	IKK LRRK2 P-glycoprotein PKD NF-κB TNF Receptor Interleukin Related	Cardiovascular Disease Inflammation/Immunology
IKK 16 is an orally active IKK inhibitor. IKK 16 shows IC₅₀s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC₅₀s of 153.9, 115, and 99.7 nM, respectively. IKK 16 is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway ^[2] .

HY-10875

LRRK2-IN-1 5+ Cited Publications	LRRK2 Apoptosis	Neurological Disease Cancer
LRRK2-IN-1 is a potent and selective *LRRK2* inhibitor with IC₅₀ of 6 nM and 13 nM for LRRK2 (G2019S) and LRRK2 (WT), respectively.

HY-148030

XL01126	PROTACs LRRK2	Neurological Disease
XL01126 is a potent *LRRK2* PROTAC (DC₅₀: 14 nM (G2019S *LRRK2) and 32 nM (WT LRRK2)) composed of the VHL ligand VH 101, thiol (HY-47851, blue part) and the LRRK2* inhibitor HG-10-102-01 (HY-13488, red part). XL01126 crosses the blood-brain barrier and is used as a degradation probe in Parkinson's disease research. XL01126 can be used to study the non-catalytic and framework functions of *LRRK2* .

HY-13237

GSK2578215A 4 Publications Verification	LRRK2 Autophagy Mitophagy	Neurological Disease Cancer
GSK2578215A is a potent and highly selective *LRRK2* inhibitor, which exhibits IC₅₀s of around 10 nM against both wild-type LRRK2 and the G2019S mutant.

HY-12477

PF-06447475 5+ Cited Publications	LRRK2	Neurological Disease
PF-06447475 is a highly potent, selective and brain penetrant *LRRK2* inhibitor with an IC₅₀ of 3 nM.

HY-12282

GNE-9605	LRRK2	Neurological Disease
GNE-9605 is a potent, orally active, selective Leucine-rich repeat kinase 2 (LRRK2) inhibitor with an IC₅₀ value of 18.7 nM. GNE-9605 inhibits LRRK2 Ser1292 autophosphorylation. GNE-9605 can be used in research of Parkinson's disease (PD) .

HY-111493

LRRK2 inhibitor 1	LRRK2	Neurological Disease
LRRK2 inhibitor 1 is a potent, selective and oral *LRRK2* inhibitor with an pIC₅₀ of 6.8.

HY-108886

JWG-071 5 Publications Verification	ERK	Cancer
JWG-071 is the kinase-selective chemical probe for ERK5. JWG-071 inhibits ERK5 and LRRK2 with IC₅₀ values of 88nM and 109 nM, respectively .

HY-18163

GNE-7915 5+ Cited Publications	LRRK2	Neurological Disease
GNE-7915 is a potent, selective and brain-penetrant inhibitor of *LRRK2* with an IC₅₀ of 9 nM.

HY-120085

PFE-360 3 Publications Verification PF-06685360	LRRK2	Neurological Disease
PFE-360 (PF-06685360) is a potent, selective, brain penetrated and orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor with a mean IC₅₀ of 2.3 nM in vivo ^[2].

HY-B0792

CZC-54252	LRRK2	Neurological Disease
CZC-54252 is a potent and selective *LRRK2* inhibitor with IC₅₀s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. CZC-54252 attenuates G2019S LRRK2-induced human neuronal injury with an EC₅₀ of ~1 nM. CZC-54252 has a neuroprotective activity .

HY-152107

LRRK2-IN-7	LRRK2	Neurological Disease
LRRK2-IN-7 is a potent, selective, and CNS-penetrant *LRRK2* kinase inhibitor with an IC₅₀ of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes .

HY-156429

MK-1468	LRRK2	Neurological Disease
MK-1468 is an orally active, selective, and BBB-permeable *LRRK2* inhibitor. MK-1468 can be used for the research of Parkinson's disease ^[2].

HY-13488

HG-10-102-01 1 Publications Verification	LRRK2 MNK	Neurological Disease
HG-10-102-01 is a highly potent, selective, and brain-penetrable *LRRK2* inhibitor, with IC₅₀ values of 20.3 and 3.2 nM against wild-type LRRK2 and *LRRK2[G2019S], respectively. HG-10-102-01 also inhibits MNK2* and MLK1, with IC₅₀ values of 0.6 and 2.1 μM. HG-10-102-01 can be used for Parkinson's disease (PD) research ^[2].

HY-14403

ERK5-IN-1	ERK	Cancer
ERK5-IN-1 is a potent ERK5 inhibitor with an IC₅₀ of 87±7 nM. ERK5-IN-1 also inhibits *LRRK2*[G2019S] with an IC₅₀ of 26 nM.

HY-15800A

CZC-25146	TNK1 LRRK2	Neurological Disease Inflammation/Immunology
CZC-25146 is a potent and orally active *LRRK2* inhibitor with IC₅₀ values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 can be used to research Parkinson's disease and liver diseases ^[2] .

HY-155150

JH-XII-03-02	LRRK2 PROTACs	Cancer
JH-XII-03-02 is a potent and selective LRRK2 PROTAC degrader. JH-XII-03-02 can be used for parkinson's Disease (PD) research .

HY-P5979

LRRKtide	LRRK2	Neurological Disease
LRRKtide is a polypeptide substrate. LRRKtide is a specific phosphorylation substrate of *LRRK2, a kinase associated with Parkinson's disease, and its phosphorylation site is a threonine residue. LRRKtide can be used for characterization of the catalytic properties of LRRK2*, as well as studies on kinase activity and inhibition. LRRKtide is applicable to research related to Parkinson's disease ^[2].

HY-13687A

IKK 16 hydrochloride Maximum Cited Publications 29 Publications Verification	IKK LRRK2 P-glycoprotein PKD NF-κB TNF Receptor Interleukin Related	Cardiovascular Disease Inflammation/Immunology
IKK 16 hydrochloride is an orally active IKK inhibitor. IKK 16 hydrochloride shows IC₅₀s of 40 nM, 70 nM, 200 nM, and 50 nM for *IKK2, IKK* complex, IKK1, and *LRRK 2, respectively. IKK 16 hydrochloride is also a pan-PKD* inhibitor, inhibiting PKD1, *PKD2, and PKD3* with IC₅₀s of 153.9, 115, and 99.7 nM, respectively. IKK 16 hydrochloride is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 hydrochloride protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 hydrochloride can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 hydrochloride attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway ^[2] .

HY-16936

JH-II-127	LRRK2	Neurological Disease
JH-II-127 is an orally active, highly potent, selective and brain-permeable *LRRK2* inhibitor, with IC₅₀s of 6, 2 and 48 nM for wild-type *LRRK2* and *LRRK2-G2019S* and mutant *LRRK2-A2016T. JH-II-127 inhibits Ser935* phosphorylation in all tissues of mice, including the brain. JH-II-127 can be used in the study of parkinson's syndrome .

HY-142647

EB-42486	LRRK2	Neurological Disease
EB-42486 is a novel, potent, and highly selective *G2019S-LRRK2* inhibitor (IC₅₀: < 0.2 nM). EB-42486 can be used in the research of Parkinson's disease ^[2].

HY-178796

*PROTAC LRRK2* Degrader-4**	PROTACs LRRK2	Neurological Disease Inflammation/Immunology
PROTAC LRRK2 Degrader-4 is a PROTAC LRRK2 degrader with a DC₅₀ of 0.79 nM. PROTAC LRRK2 Degrader-4 can be used for research in Parkinson’s disease and inflammation .

HY-178797

*PROTAC LRRK2* Degrader-3**	PROTACs LRRK2	Neurological Disease Inflammation/Immunology
PROTAC LRRK2 Degrader-3 (compound 6) is a PROTAC LRRK2 degrader with a DC₅₀ of 0.17 nM. PROTAC LRRK2 Degrader-3 can be used for research in Parkinson’s disease and inflammation .

HY-132969

SBP-3264 2 Publications Verification	Hippo (MST) YAP	Cancer
SBP-3264 is a YAP activator and STK/MST inhibitor with IC₅₀ values of 36 nM against *STK3/MST2* and 24 nM against STK4/MST1. SBP-3264 modulates the Hippo signaling pathway. SBP-3264 can be used for the research of acute myeloid leukemia .

HY-153058

LRRK2-IN-8	LRRK2 JAK AMPK	Neurological Disease Cancer
LRRK2-IN-8 is a *LRRK2* inhibitor. LRRK2-IN-8 inhibits LRRK2 (wt) and LRRK2 (G2019) with IC₅₀s lower than 10 nM, and inhibits *TYK2* and NUAK1 with IC₅₀s of 10-100 nM .

HY-112855

PF-06454589	LRRK2	Neurological Disease
PF-06447475 is a highly potent, selective, brain penetrant LRRK2 kinase inhibitor with IC₅₀ values of 3 nM and 11 nM for WT LRRK and G2019S LRRK2, respectively. PF-06447475 can be used for parkinson's disease (PD) research .

HY-18163A

GNE-7915 tosylate 5+ Cited Publications	LRRK2	Neurological Disease
GNE-7915 tosylate is a potent, selective and brain-penetrant inhibitor of *LRRK2* with an IC₅₀ of 9 nM.

HY-134562

PF-06371900	LRRK2	Neurological Disease
PF-06371900 is a potent and highly selective leucine rich repeat kinase 2 (LRRK2) inhibitor .

HY-B0792A

CZC-54252 hydrochloride	LRRK2	Neurological Disease
CZC-54252 hydrochloride is a potent and selective *LRRK2* inhibitor with IC₅₀s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. G2019S LRRK2-induced human neuronal injury is attenuated by CZC-54252 hydrochloride with an EC₅₀ of ~1 nM.CZC-54252 hydrochloride has a neuroprotective activity .

HY-W002458

4-Nitropyrazole	Drug Intermediate	Others
4-Nitropyrazole is a five-membered nitrogen-containing heterocyclic compound that can be used as a drug intermediate. 4-Nitropyrazole can be synthesized into antibiotics/antifungal/antiviral agents containing pyrazole rings. 4-Nitropyrazole is synthesized through C-H activation reactions to produce LRRK2 inhibitors, which are used in the research of Parkinson's disease ^[2] .

HY-112809

GSK2646264	Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase	Inflammation/Immunology
GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.1. GSK2646264 also inhibits other kinases with pIC₅₀ values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, *LRRK2, GSK3β, JAK2, VEGFR2, Aurora B* and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .

HY-152107A

*(R,R)-LRRK2-IN-7*	LRRK2	Neurological Disease
(R,R)-LRRK2-IN-7 is the isomer of LRRK2-IN-7 (HY-152107). LRRK2-IN-7 is a potent, selective, and CNS-penetrant LRRK2 kinase inhibitor with an IC50 of 0.9 nM. LRRK2-IN-7 shows >1000-fold selectivity over other kinases, ion channels, and CYP enzymes.

HY-175651

LRRK2-IN-20	LRRK2	Neurological Disease
LRRK2-IN-20 (EX. 4.64) is a *LRRK2* inhibitor with a pIC₅₀ of 0.7921 nM. LRRK2-IN-20 can be used in Parkinson's disease (PD) research .

HY-161571

LRRK2-IN-13	LRRK2	Neurological Disease
LRRK2-IN-13 (Compound 13) is an inhibitor of *LRRK2* (IC₅₀=0.57 nM). LRRK2-IN-13 has brain penetrating properties .

HY-161570

LRRK2-IN-12	LRRK2	Neurological Disease
LRRK2-IN-12 (compound 1) inhibits the activity of LRRK2 G20195 (IC₅₀=0.45 nM), LRRK2 WT (IC₅₀=1.1 nM) and LRRK2 WT ADP-Glo (IC₅₀=0.46 nM). LRRK2-IN-12 can be used for Alzheimer's Disease research .

HY-174427

RN341	LRRK2	Neurological Disease
RN341 is a specific type II kinase inhibitor of *LRRK2* (IC₅₀: 296 nM). RN341 inhibits *LRRK2* phosphorylation and avoids S935 dephosphorylation by stabilizing the open conformation. RN341 rescues *LRRK2*-mediated kinesin motility block by preventing microtubule binding. RN341 effectively inhibits *LRRK2* wild-type and G2019S mutant at the cellular level. RN341 provides a new direction for Parkinson's disease research.

HY-177016

LRRK2-IN-19	Ligands for Target Protein for PROTAC LRRK2	Neurological Disease
LRRK2-IN-19 is a PROTAC target protein ligand that can be used to synthesize PROTAC JH-XII-03-02 (HY-155150). JH-XII-03-02 is a highly potent and selective *LRRK2* PROTAC degrader, which can be used in Parkinson's disease research .

HY-174420

RN277	LRRK2	Neurological Disease
RN277 is an inhibitor for LRRK2 type II kinase. RN277 can be used as a cellular tool targeting the LRRK2 inactive state. RN277 can inhibit LRRK1 kinase activity in vitro. RN277 inhibits LRRK2 kinase activity in vitro (IC₅₀ = 70 nM). RN277 reduces phosphorylation of Rab8a dose-dependently. RN277 can be studied in research for Parkingson’s disease .

HY-158365

LRRK2-IN-14	LRRK2	Neurological Disease
LRRK2-IN-14 (Compound 8) is an orally active *LRRK2* inhibitor. LRRK2-IN-14 has an IC₅₀ of 6.3 nM for LRRK2(G2019S) cell activity.LRRK2-IN-14 has an inhibitory effect on hERG (IC₅₀=22 μM). LRRK2-IN-14 has blood-brain barrier permeability .

HY-RS07834

Lrrk2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Lrrk2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Lrrk2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lrrk2 Mouse Pre-designed siRNA Set A Lrrk2 Mouse Pre-designed siRNA Set A

HY-RS07835

Lrrk2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Lrrk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Lrrk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Lrrk2 Rat Pre-designed siRNA Set A Lrrk2 Rat Pre-designed siRNA Set A

HY-RS07833

LRRK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
LRRK2 Human Pre-designed siRNA Set A contains three designed siRNAs for LRRK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LRRK2 Human Pre-designed siRNA Set A LRRK2 Human Pre-designed siRNA Set A

HY-145317

LRRK2-IN-2	LRRK2	Neurological Disease
LRRK2-IN-2 (compoubd 22) is a potent, selective, orally active and brain-penetrant inhibitor *LRRK2, with IC₅₀* of <0.6 nM. LRRK2-IN-2 can be used for the research of Parkinson's disease .

HY-145318

LRRK2-IN-3	LRRK2	Neurological Disease
LRRK2-IN-3 (compoubd 24) is a potent, selective, orally active and brain-penetrant inhibitor *LRRK2, with IC₅₀* of 2.6 nM in human PBMCs. LRRK2-IN-3 can be used for the research of Parkinson's disease .

HY-144074

LRRK2-IN-4	LRRK2	Neurological Disease
LRRK2-IN-4 is a potent, selective, CNS-penetran and orally active leucine-rich repeat kinase 2 (LRRK2) inhobitor with an IC₅₀ of 2.6 nM. LRRK2-IN-4 has the potential for the research of Parkinson’s disease .

HY-186110

*PROTAC LRRK2* Degrader-5**	PROTACs LRRK2	Neurological Disease
PROTAC LRRK2 Degrader-5 Formula (V) is a LRRK2 PROTAC degrader. PROTAC LRRK2 Degrader-5 can be used for thet study of the diseases associated with LRRK2, such as Parkinson’s Disease (PD) .

HY-153103

LRRK2/NUAK1/TYK2-IN-1	LRRK2 JAK AMPK	Inflammation/Immunology
LRRK2/NUAK1/TYK2-IN-1 (conpound 226) shows inhibitory activity toward LRRK2 (Wt), LRRK2 (G2019), *TYK2* and NUAK1, with IC₅₀ values lower than 10 nM. LRRK2/NUAK1/TYK2-IN-1 can be used for autoimmune disease research .

HY-171802

*PROTAC LRRK2* Degrader-2**	PROTACs LRRK2	Neurological Disease
PROTAC LRRK2 Degrader-2 is a PROTAC-based degrader targeting *LRRK2* with a DC₅₀ of 0.14 nM. PROTAC LRRK2 Degrader-2 recruits *LRRK2* or its mutants to the cereblon E3 ubiquitin ligase, thereby mediating the targeted ubiquitination and subsequent proteasomal degradation of *LRRK2. PROTAC LRRK2* Degrader-2 can be used in research related to Parkinson's disease .

Cat. No.	Product Name

HY-L029

Autophagy Compound Library

1,996 compounds

Autophagy is a lysosomal degradation pathway that is essential for cell survival, differentiation, development, and homeostasis. The process of autophagy in mammalian cells is as follows: a portion of cytoplasm, including organelles, is enclosed by a phagophore or isolation membrane to form an autophagosome. The outer membrane of the autophagosome subsequently fuses with the endosome and then the lysosome, and the internal material is degraded. Autophagy plays a wide variety of physiological and pathophysiological roles. Defective autophagy contributes to various pathologies, including infections, cancer, neurodegeneration, aging, and heart disease.

MCE provides a unique collection of 1,996 autophagy pathway-related compounds that is a useful tool for the research of autophagy-related regulation and diseases.

HY-L085

Anti-Parkinson's Disease Compound Library

2,113 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 2,113 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.

HY-L086

Neurodegenerative Disease-related Compound Library

3,605 compounds

Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour.

MCE offers a unique collection of 3,605 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

Cat. No.	Product Name	Target	Research Area

HY-P5979

LRRKtide	LRRK2	Neurological Disease
LRRKtide is a polypeptide substrate. LRRKtide is a specific phosphorylation substrate of *LRRK2, a kinase associated with Parkinson's disease, and its phosphorylation site is a threonine residue. LRRKtide can be used for characterization of the catalytic properties of LRRK2*, as well as studies on kinase activity and inhibition. LRRKtide is applicable to research related to Parkinson's disease ^[2].

HY-P10636

Nictide	LRRK2	Others
Nictide is a peptide substrate of LRRK2 (leucine-rich repeat protein kinase-2). Nictide can be phosphorylated by the activated LRRK2[G2019S] with a Km of 10 μM .

HY-P11780

KAFDITYVRLKF	Integrin MMP	Neurological Disease Cancer
KAFDITYVRLKF is a selective, competitive integrin α_vβ₃ binder. KAFDITYVRLKF induces the production of MMP-9. KAFDITYVRLKF blocks monocyte migration, promotes melanoma cell migration, protects neurons, and improves motor and cognitive functions. KAFDITYVRLKF can be used in research related to melanoma and Parkinson's disease ^[2].

Recombinant Proteins Recommended:

LRRK2

Species:	Human (2)
Tag:	His (1) GST (2)
Source:	Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P706065

	LRRK2 Protein, Human (Active, sf9, His-GST) Leucine-rich repeat serine/threonine-protein kinase 2; Dardarin; PARK8	Human	Sf9 insect cells

HY-P703644

	LRRK2 Protein, Human (Active, G2019S, sf9, GST) PARK8	Human	Sf9 insect cells
	LRRK2 Protein, Human (sf9, GST, G2019S) is the recombinant human-derived LRRK2, expressed by sf9 insect cells , with GST labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (4) Rabbit (4)
Reactivity:	Human (8) Rat (1) Mouse (4)
Application:	IHC-P (4) ICC/IF (6) IP (1) WB (4) FC (5) ELISA (5)
Isotype:	IgG,Kappa (1) IgG (3) IgG1 (4)
Conjugation:	Non-conjugated (8)
Clonality:	Monoclonal (5) Recombinant (3)
Modification:	Phosphorylated (1) Unmodified (5)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P87686

	LRRK2 Antibody (YA7371)	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	LRRK2 Antibody (YA7371) is a Rabbit-derived and non-conjugated IgG, Kappa monoclonal antibody, targeting to LRRK2.

HY-P83076A

	*Phospho-LRRK2(Ser935) Antibody (YA3424)* AURA17; Dardarin antibody; ; Leucine rich repeat kinase 2; LRRK 2 antibody; LRRK2; LRRK2_HUMAN; PARK 8; PARK8; RIPK7; ROCO 2; ROCO2	WB, ICC/IF	Human, Mouse
	Phospho-LRRK2(Ser935) Antibody (YA3424) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-LRRK2(Ser935).

HY-P83076

	LRRK2 Antibody (YA2821) AURA17; Dardarin antibody; ; Leucine rich repeat kinase 2; LRRK 2 antibody; LRRK2; LRRK2_HUMAN; PARK 8; PARK8; RIPK7; ROCO 2; ROCO2	WB, IHC-P, ICC/IF	Human, Mouse
	LRRK2 Antibody (YA2821) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LRRK2.

HY-P84632

	LRRK2 Antibody (YA4329) PARK8; RIPK7; ROCO2; AURA17; DARDARIN	ICC/IF, FC, ELISA	Human
	LRRK2 Antibody (YA4329) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LRRK2.

HY-P84633

	LRRK2 Antibody (YA4330) PARK8; RIPK7; ROCO2; AURA17; DARDARIN	IHC-P, FC, ELISA	Human
	LRRK2 Antibody (YA4330) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LRRK2.

HY-P810542

	*Phospho-LRRK2* (Ser935) Antibody (YA9811)** AURA17; Dardarin; ; Leucine rich repeat kinase 2; LRRK 2; LRRK2; LRRK2_HUMAN; PARK 8; PARK8; RIPK7; ROCO 2; ROCO2	WB, ICC/IF, FC	Human, Mouse
	Phospho-LRRK2 (Ser935) Antibody (YA9811) is a Rabbit-derived and non-conjugated IgG Recombinant, Monoclonal antibody, targeting to Phospho-LRRK2 (Ser935).

HY-P84632A

	LRRK2 Antibody (YA4329)(PBS only) PARK8; RIPK7; ROCO2; AURA17; DARDARIN	ICC/IF, FC, ELISA	Human
	LRRK2 Antibody (YA4329) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LRRK2.

HY-P84633A

	LRRK2 Antibody (YA4330)(PBS only) PARK8; RIPK7; ROCO2; AURA17; DARDARIN	IHC-P, FC, ELISA	Human
	LRRK2 Antibody (YA4330) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to LRRK2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: